Global /China /Healthcare /Drug Manufacturers - General /002262

Jiangsu Nhwa Pharmaceutical Co., LTD.

002262

• SHE: 002262 • Delayed

22.42CNY 0%

3.31 USD

As of 7 June 2026, Jiangsu Nhwa Pharmaceutical Co., LTD. has a market cap of $3.36B USD, ranking #5021 globally and #1056 in China. It ranks #391 in the Healthcare sector, and #152 in the Drug Manufacturers - General industry.

Global Rank

5021

Country Rank

1056

Sector Rank

391

Industry Rank

152

Key Stats

Market Cap

$3.36BUSD

22.76B CNY

Enterprise Value

$2.76BUSD

18.7B CNY

Revenue (TTM)

$887.89MUSD

6.01B CNY

EBITDA (TTM)

$190.73MUSD

1.29B CNY

Net Income (TTM)

$158.66MUSD

1.07B CNY

EBITDA Margin

21%

Profit Margin

18%

PE Ratio

21.1

Forward PE

17.6

PS Ratio

3.8

PB Ratio

2.7

EV/EBITDA

14.2

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jiaquan Sun open_in_new

Employees

6,003

Founded

1978

Website

nhwa-group.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	4.9%	0.2%	-5.2%	-8.9%	-7.1%	-18%	-21%	42%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	002262 江苏恩华药业股份有限公司 Class A ISIN: CNE100000CG8 Shares Out.: Shares Outstanding: 1.01B¹ Shares Float: 556.224M² TV: TradingView: SZSE: 002262 SA: Stock Analysis: SHE: 002262 YF: Yahoo Finance: 002262.SZ GF: Google Finance: SHE: 002262 BA: Barron's: 002262 MS: Morningstar: XSHE: 002262	22.42 CNY	TV: TradingView: SZSE: 002262 SA: Stock Analysis: SHE: 002262 YF: Yahoo Finance: 002262.SZ GF: Google Finance: SHE: 002262 BA: Barron's: 002262 MS: Morningstar: XSHE: 002262

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Jiangsu Nhwa Pharmaceutical Co., LTD.

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.9B 364.89B CNY 2K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.69B 336.36B CNY 1K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 748%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 459%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.53B 111.89B CNY 392%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 376%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 23K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 16K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 11K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 10K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 9K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 8K%	20.5	Switzerland

chevron_leftBack